Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVM-V001 booster in healthy adults
NCT05420077Phase 1Terminated
- Sponsor
- RVAC Medicines
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of RVM-V001 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by RVAC Medicines. Primary endpoints: Number of subjects with solicited adverse events, Number of subjects with unsolicited adverse events and 6 more. Started Sep 2022; status: terminated.
02
Drugs
RVM-V001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05420077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420077.